{"disease":{"id":"locally-advanced-or-metastatic-cancers","name":"locally advanced or metastatic cancers"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05356741","title":"To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":645,"lead_sponsor_name":"Vir Biotechnology, Inc.","has_results":false},{"nct_id":"NCT04799054","title":"A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":188,"lead_sponsor_name":"Ascendis Pharma Oncology Division A/S","has_results":false},{"nct_id":"NCT04958434","title":"Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":19,"lead_sponsor_name":"Suzhou Transcenta Therapeutics Co., Ltd.","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}